Decision spine
Frames the controlling thesis, evidence status, buyer implications, and research-use limits.
Emerging Med Tech
Zemi Dossier
Research-use only
Partial Epigenetic Reprogramming
A decision package on the narrow margin between rejuvenation signal and transformation risk in partial reprogramming strategies.
Decision this dossier helps answer
Which partial-reprogramming programs have enough control, reversibility, and safety-margin evidence to justify next validation?
Problem this dossier solves
The same dial can point toward repair or risk.
The dossier treats partial reprogramming as a margin-width problem: how much rejuvenation signal can be gained before identity, proliferation, or transformation risk dominates. The decision package forces clock movement to face functional and safety gates.
What is moving: current field evidence and platform activity
What is unresolved: decision-grade proof, endpoint logic, and failure modes
What Zemi solves: evidence-gated next-study strategy
Full decision package
120-page research report plus 38-sheet Evidence & Decision Workbook
Buy now
$3,500$5,500Launch price
Controlling thesis
The same dial can point toward repair or risk.
The dossier treats partial reprogramming as a margin-width problem: how much rejuvenation signal can be gained before identity, proliferation, or transformation risk dominates. The decision package forces clock movement to face functional and safety gates.
A Zemi Dossier turns uncertain emerging research into a decision package: what is known, what is inferred, what is hypothetical, what would falsify the thesis, and what should be built, funded, avoided, monitored, or validated next.
Research report preview
First 30 pages of the actual Partial Epigenetic Reprogramming research report.
The public page shows the real document style, density, evidence posture, and decision framing before a buyer requests access to the full Zemi Dossier package.
Research report
The research report is the argument. It is not the whole product.
The PDF research report is the structured argument: field status, evidence maturity, buyer implications, falsifiable hypotheses, power-calculated next studies, strategic recommendations, limitations, and traceability posture.
Inspectable infrastructure
Pairs the report with claim ledgers, evidence tables, power rows, audit surfaces, and decision tools.
Executable next studies
Links hypotheses to endpoint logic, assumptions, sample-size logic, budget, and timeline planning.
Research report table of contents
Public TOC generated from the source report.
The full research report is delivered as a licensed PDF. This table shows the decision structure without publishing the full product.
| Section | What it covers | Buyer value |
|---|---|---|
| Contents | Shows the report structure and where to inspect the argument, evidence, workbook logic, and limits. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Executive Summary | Condenses the dossier thesis, evidence posture, buyer implications, and next-study priorities. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Decision Brief Read This First | Turns the report into immediate buyer triage: what matters now, what is still uncertain, and what to do next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Scope and Evidence Integrity | Defines the evidence window, source boundaries, research-use limits, and labeling discipline. | Lets the buyer audit support strength before relying on the package. |
| Decision Snapshot Overview | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Buyer Decision Matrix | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Buy Build Wait Avoid | Maps findings to buyer actions: build, fund, avoid, monitor, or validate next. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Source Quality Dashboard | Shows how strong the source base is and where conclusions depend on indirect or thinner support. | Lets the buyer audit support strength before relying on the package. |
| The Rejuvenation Transformation Index | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The fifth element: the Relocation corollary (June 2026) | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Rtm Margin Classifier | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Quantitative Margin Index | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| The Relocation Detection Assay | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| The Organ Bifurcation Theorem | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Current Signal Update 2025 2026 | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Current Signal Refresh | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Axis Convergence Map | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Two couplings the 2026 frontier adds | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Cross Domain Synthesis | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Competing Interpretations Adjudicated | Compares alternative readings of the evidence and explains why the dossier weights one interpretation over another. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Evidence Maturity and Platform Matrix | Links claims to source support so users can separate what is known, inferred, and hypothetical. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Comparative Platform Mechanism Matrix | Operationalizes the thesis as a reusable decision surface for comparing programs or evidence states. | Gives the buyer a reusable way to compare programs, risks, and evidence states. |
| Competitive Landscape | Frames the field's June 2026 state, active programs, research fronts, and timing signals. | Connects research claims to practical diligence and monitoring decisions. |
| Key Findings | Summarizes the most decision-relevant findings and their implications for the dossier thesis. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Foundational | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Mechanism: the single dial | Explains which biological signals matter for interpreting the field and discriminating between programs. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Established efficacy (animal) | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Q1: reset without identity loss | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Q1: the cancer-risk frontier | Defines the governing argument and the evidence gates that would support or falsify it. | Shows where the thesis could fail or require more validation before action. |
| Q2: clock vs function | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Q2: clock reliability | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Q2: the functional bridge | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Q2: function exists | Summarizes a report component that ties field evidence to the dossier's decision logic. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Law 3: margin-width triage | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Law 4: non-cell-autonomy | Defines the governing argument and the evidence gates that would support or falsify it. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
| Coupling 7: durability | Shows how separate research signals converge, diverge, or interact across domains, mechanisms, or study layers. | Helps the buyer inspect the argument, evidence posture, and decision logic before relying on the package. |
Evidence & Decision Workbook
The workbook is the decision engine.
A locked public preview of selected workbook-derived sheets: sheet structure, decision modules, power rows, traceability, and audit posture. Licensed buyers receive the full workbook files.
Read-only workbook preview with clipped values and no formulas. Licensed buyers receive the full Evidence & Decision Workbook with editable assumptions and working files.
Workbook inventory
Delivered workbook sheets.
Full inventories belong on dossier pages, not the homepage. Sheet names below are extracted from the actual workbook file.
| # | Workbook sheet | What it does |
|---|---|---|
| 1 | 1. Workbook Guide | Navigation layer for using the workbook, understanding sheet roles, and following the decision package. Public preview exposes Point-in-time, June 2026 - evidence window to. fields and clipped entries such as Source-audit reconciliation, 132 audited = 61. |
| 2 | 2. Claim Ledger | Claim-by-claim ledger showing verdicts, source support, inference status, and decision relevance. Public preview exposes claim_id, report_section, report_page, claim_text fields and clipped entries such as CL-001, Mechanistic Deep Dive - the single., p.110. |
| 3 | 3. Evidence Table | Evidence-verification surface for checking sources, support quality, and the audit trail. Public preview exposes NCT:NCT03601052, A Phase 2, Double-blind,., ClinicalTrials.gov, 2018-06-11 fields and clipped entries such as NCT:NCT05398029, Open-label, Phase. |
| 4 | 4. Source-Support Verdicts | Independent check on whether key claims are actually supported by cited sources. Public preview exposes claim_id, Primary cite, Finding, Source-support verdict (6-way) fields and clipped entries such as CL-001, PMID:40354373, Finding 1 — Partial OSKM.. |
| 5 | 5. Source-Quality Summary | Summary of source strength, gaps, and areas where conclusions depend on weaker evidence. Public preview exposes Customer-facing sources, 52 fields and clipped entries such as Fresh value-based grade - High, Fresh value-based grade - Moderate. |
| 6 | 6. Organ & RTI Scorecard | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Organ, Tissue property, Predicted margin, Maturity fields and clipped entries such as Retina / optic nerve, post-mitotic·cell-autonomous, Wide. |
| 7 | 7. Organ-Strategy Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Ex-vivo organ, First human EFFICACY route -., high (explant), perfusion fields and clipped entries such as Marrow/gut/systemic, AVOID first -. |
| 8 | 8. Asset & Company Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company / asset, Modality, Stage, Disclosed capital fields and clipped entries such as Life Biosciences / ER-100, doxycycline-inducible OSK (AAV),. |
| 9 | 9. Trial-IND-Catalyst Tracker | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes NCT, Title, Phase, Status fields and clipped entries such as NCT03601052, A Phase 2, Double-blind,., PHASE2. |
| 10 | 10. Oncogenicity-Window | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Oncogenic mechanism, Over vs aborted, Highest-risk organ, Signal fields and clipped entries such as Over-reset -> de-diff /. |
| 11 | 11. Clock-Biomarker Tracker | Tracks biomarkers or readouts that determine whether the thesis is moving toward testable evidence. Public preview exposes Clock / biomarker, Measures, Tissue, Clock-vs-function fields and clipped entries such as GrimAge / 1st-2nd gen DNAm, mortality-trained. |
| 12 | 12. Delivery-Durability Tracker | Captures failure modes and constraints that could invalidate or narrow a program. Public preview exposes Modality, Confinement, Temporal control, Expression window fields and clipped entries such as AAV-OSK (engineered capsid), tissue (capsid), low. |
| 13 | 13. Senescence-Convergence | Workbook surface supporting a specific evidence, decision, study-planning, or release-control workflow. Public preview exposes Finding, Role, Mechanism, Implication fields and clipped entries such as p16-high cells resist full., safety brake, resistance to. |
| 14 | 14. Regulatory-Endpoint Tracker | Tracks regulatory, endpoint, reimbursement, or qualification requirements that shape testing strategy. Public preview exposes Item, Status / channel (named), Note, Source fields and clipped entries such as Aging as an indication, NONE - no FDA pathway, no. |
| 15 | 15. Figure Source Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes Fig #, File name, Caption (as rendered), Anchor section fields and clipped entries such as fig04_capital_asymmetry.png, Figure 1. The. |
| 16 | 16. Figure Attempt Ledger | Figure and numeric reproduction log for validating calculations, chart inputs, or displayed values. Public preview exposes Fig #, Figure ID, Backend, Data type fields and clipped entries such as fig04_capital_asymmetry, deterministic, verified-quantitative. |
| 17 | 17. Hypotheses Ledger | Maps hypotheses to evidence state, falsification logic, endpoints, and next-study design. Public preview exposes ID, Tier, Paradigm, Title (novelty) fields and clipped entries such as F1, Flagship, margin-width triage. |
| 18 | 18. MV Next Studies | Prioritizes next studies that could change the decision, including endpoints and evidence gates. Public preview exposes Study, Question settled, Design, Decisiveness fields and clipped entries such as NHP organ-margin panel, Can the margin be measured. |
| 19 | 19. Verification-Search Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes Source/DB, Query / action, Result, Note fields and clipped entries such as VERIFY, PubMed/NCBI esummary+efetch (PMIDs), 96 PMIDs. |
| 20 | 20. Excluded Claims (71) | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Claim label, Bucket, Citations, Reason fields and clipped entries such as Excluded 12 — Personalized biomarker., off-topic. |
| 21 | 21. Quarantined Sources | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Finding, Source, Reason, Disposition fields and clipped entries such as F10 - NEI Ocular Gene Therapy Core, (no citation),. |
| 22 | 22. Salvage Ledger | Disposition log for rejected, bounded, or quarantined claims so they do not leak into the decision thesis. Public preview exposes Recovered item, Type, How grounded, Source fields and clipped entries such as Life Biosciences' ER-100 became (per., structural. |
| 23 | 23. Power Calculations | Power-calculation layer for assumptions, endpoint logic, computed sample sizes, and sensitivity checks. Public preview exposes hypothesis_id, study_id, endpoint, test_type fields and clipped entries such as F1, STUDY-F1, Margin width per organ = (cumulative.. |
| 24 | RTM_Input_Template | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Endpoint availability, functional readout exists?., ____ fields and clipped entries such as Aborted-trajectory risk, pulse schedule; dwell time at. |
| 25 | RTM_Feature_Score | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes ENDPOINT-FORECLOSED-LIMITED, Endpoint foreclosure: functional., 1, 1.1 fields and clipped entries such as ABORTED-TRAJECTORY-LIMITED,. |
| 26 | RTM_Class_Output | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Clock-only program (no functional., ENDPOINT-FORECLOSED-LIMITED, PROLIFERATIVE-ONCOGENIC-LIMITED, ENDPOINT-FORECLOSED-LIMITED fields and clipped. |
| 27 | RTM_Decision_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Class (binding constraint), Recommended strategy, Primary functional endpoint, Required safety readout fields and clipped entries such as. |
| 28 | RTM_Context_Rules | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Checkpoint/field status (input., Disposition, Contraindication / strategy, Safety flag fields and clipped entries such as checkpoint-intact,. |
| 29 | RTM_Minimum_Assay_Panel | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Functional readout availability +., Endpoint, Required fields and clipped entries such as Organ-specific proteomic clock., Endpoint (bridge),. |
| 30 | RTM_Archetype_Cards | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Marrow / CHIP-TP53, oncogenic 3; field TP53, REPROGRAMMING CONTRAINDICATED, Do NOT reprogram (TF route); run. fields and clipped entries such as. |
| 31 | RTM_Validation_Log | Executable decision surface for classifying programs, risks, gates, or evidence states. Public preview exposes Functional endpoint, organ-specific >=10% functional. fields and clipped entries such as Beats baseline?, the falsification test: the.. |
| 32 | RTM_Traceability_Map | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes RTM element, Maps to claim/finding, Evidence ID, Figure fields and clipped entries such as Oncogenic-pressure factor, margin-width law;. |
| 33 | 33. Traceability Certificate | Traceability surface linking claims, figures, calculations, and workbook outputs back to sources. Public preview exposes claim_id, report_section, report_page, claim_text fields and clipped entries such as CL-001, Mechanistic Deep Dive - the single., p.110. |
| 34 | 34. Score Basis | Explains how scores or ratings were assigned so the decision instrument can be inspected. Public preview exposes Organ RTI scorecard (fig29), margin Wide/Moderate/Narrow, proliferative index x. fields and clipped entries such as RTM_Feature_Score. |
| 35 | 35. Competitive Landscape | Tracks programs, trials, sponsors, or competitive context for diligence and monitoring. Public preview exposes Company, Asset / platform, Modality, Organ fields and clipped entries such as Life Biosciences, ER-100 (OSK partial reprogramming), AAV gene. |
| 36 | 36. Version Registry | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes v1.0, June 2026, Initial build + audit (Blended., - fields and clipped entries such as Model, RTI v2.0 + Relocation corollary, 4 laws. |
| 37 | 37. Audit Issues Log | Release-discipline surface for revisions, unresolved issues, audit findings, and readiness tracking. Public preview exposes #, Issue, Status, Resolution fields and clipped entries such as AI-1, Workbook genuinely executable?, RESOLVED. |
| 38 | 38. Currentness Scan | Monitoring surface for emerging signals, update triggers, and evidence changes that could alter the decision. Public preview exposes June-2026 signal, Date, Present / Stale / Missing, Dossier treatment fields and clipped entries such as Life Biosciences. |
Power-calculated next studies
Power calculations are the execution bridge.
Power calculations are planning-grade research calculations for endpoint logic, assumptions, sample size, budget, and timeline. They do not prove hypotheses or constitute clinical protocol.
| Hypothesis | Primary endpoint | Test | Effect | α | Power | Computed n | Design n |
|---|---|---|---|---|---|---|---|
| F1 | Margin width per organ = (cumulative exposure at first oncogenic/atyp... | AUC (Hanley-McNeil, external) | 0.8 | 0.05 | 0.80 | 28 | 60 |
| F2 | Ratio of eye to marrow margin width (exposure-to-first-atypia minus e... | Two-sample means | 1.5 | 0.05 | 0.80 | 7 | 8 |
| F3 | C-index for incident multi-system functional decline, proteomic vs DN... | Two-sample means | 0.55 | 0.05 | 0.80 | 52 | 60 |
| F4 | Organ-specific functional gain (retinal ganglion-cell electrophysiolo... | Two-sample means | 1.0 | 0.05 | 0.80 | 16 | 16 |
| F5 | Incidence of early allograft dysfunction, reprogramming-perfusion vs ... | Two-proportion | 0.3 | 0.05 | 0.80 | 121 | 124 |
Release audit discipline
Audit posture is part of the product.
Public pages do not publish exact audit scores. They should state the release discipline, revision posture, and limitations without implying peer review or validated clinical guidance.
Research-use decision package
Not medical advice, clinical guidance, investment advice, or a clinical protocol.
Known / inferred / hypothetical
The package separates cited evidence from inference and frontier hypothesis generation.
Audit-gated and revision-controlled
Adversarial audit checks source support, formulas, figures, limitations, and release readiness.
Buy this dossier
Full decision package — 120-page report + 38-sheet workbook
Buy now
- Decision research report (120 pages, PDF)
- Evidence & Decision Workbook (38 sheets, .xlsx) — claims, source-support verdicts, power calculations, traceability, and audit log
- Live, editable power-calculated next studies
$3,500$5,500Launch price